- Home
- LESL vs INKT Comparison
LESL vs INKT Comparison
Compare LESL & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LESL
- INKT
- Stock Information
- Founded
- LESL 1963
- INKT 2017
- Country
- LESL United States
- INKT United States
- Employees
- LESL N/A
- INKT N/A
- Industry
- LESL Diversified Commercial Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- LESL Miscellaneous
- INKT Health Care
- Exchange
- LESL Nasdaq
- INKT Nasdaq
- Market Cap
- LESL 66.9M
- INKT 69.2M
- IPO Year
- LESL 2020
- INKT 2021
- Fundamental
- Price
- LESL $3.96
- INKT $14.20
- Analyst Decision
- LESL Hold
- INKT Buy
- Analyst Count
- LESL 9
- INKT 3
- Target Price
- LESL $33.25
- INKT $37.50
- AVG Volume (30 Days)
- LESL 198.8K
- INKT 28.2K
- Earning Date
- LESL 11-24-2025
- INKT 11-13-2025
- Dividend Yield
- LESL N/A
- INKT N/A
- EPS Growth
- LESL N/A
- INKT N/A
- EPS
- LESL N/A
- INKT N/A
- Revenue
- LESL $1,250,568,000.00
- INKT N/A
- Revenue This Year
- LESL N/A
- INKT N/A
- Revenue Next Year
- LESL N/A
- INKT N/A
- P/E Ratio
- LESL N/A
- INKT N/A
- Revenue Growth
- LESL N/A
- INKT N/A
- 52 Week Low
- LESL $3.50
- INKT $4.56
- 52 Week High
- LESL $72.60
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- LESL 55.65
- INKT 47.12
- Support Level
- LESL $3.50
- INKT $14.01
- Resistance Level
- LESL $4.52
- INKT $15.25
- Average True Range (ATR)
- LESL 0.38
- INKT 0.70
- MACD
- LESL -0.17
- INKT 0.01
- Stochastic Oscillator
- LESL 33.33
- INKT 24.88
About LESL Leslie's Inc.
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products across chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company offers its products and services for Residential Pool, Residential Spa, Professional Pool, and Commercial Pool consumers. Geographically, it operates only in the United States.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.